Based on this assumption and given the likelyhood that ERα positively regulates p53TMEM26 expression as suggested by the data obtained by fulvestrant (Figure 3B, 3C), it makes sense that TMEM26-specific immunoreactivity in breast cancer specimens correlates with ERα- and PR-positivity. This evidence concerns the gene ESR1 and breast carcinoma.